Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the Tourmaline-MM3 Trial

Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).